First-in-human antibody-drug conjugate targeting tumor-associated MUC1 (TA-MUC1); a humanized monoclonal antibody delivers an intracellular cytotoxic payload after antigen-mediated internalization to kill TA-MUC1-positive tumor cells. Administered IV every 3 weeks in advanced/metastatic solid tumors.
DS-3939a is an ADC comprising a humanized antibody targeting tumor-associated MUC1 (TA-MUC1) linked via a cleavable peptide linker to the topoisomerase I–inhibiting payload DXd. After binding TA-MUC1 on tumor cells and internalization, lysosomal cleavage releases DXd, which stabilizes the topoisomerase I–DNA complex, causing DNA breaks, replication arrest, and apoptosis of TA-MUC1–expressing tumor cells.
The ADC binds TA-MUC1 on tumor cells, is internalized, and its cleavable linker is degraded in lysosomes to release the DXd topoisomerase I inhibitor, which induces DNA breaks, replication arrest, and apoptosis of TA-MUC1-expressing cells.
Fully human anti-CD20 monoclonal antibody that depletes CD20+ B cells via complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity.
Fully human anti-CD20 IgG1 monoclonal antibody that binds CD20 on B cells and depletes CD20+ B cells via complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC).
Ofatumumab binds CD20 on B cells, activates complement to induce membrane attack complex–mediated lysis (CDC) and engages Fcγ receptors on effector cells (e.g., NK cells, macrophages) to drive ADCC and phagocytosis, killing CD20+ cells.
Human anti-CD38 monoclonal antibody that depletes plasma cells via complement-, antibody-, and phagocytosis-mediated cytotoxicity and apoptosis; may modulate T-cell function.
Daratumumab is a human IgG1-kappa monoclonal antibody targeting CD38. Binding to CD38 on plasma cells and other CD38+ cells triggers complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and apoptosis, leading to depletion of CD38-expressing cells and immunomodulation.
Binds CD38 on target cells and induces complement-dependent cytotoxicity (CDC), NK cell–mediated ADCC, macrophage ADCP, and can trigger apoptosis, killing CD38+ cells.
Chimeric anti-CD20 monoclonal antibody that depletes CD20+ B cells via antibody-dependent cellular cytotoxicity, complement activation, and apoptosis to reduce pathogenic autoantibody production.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on pre-B and mature B cells and depletes them via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis, thereby reducing pathogenic autoantibody production.
Rituximab binds CD20 on B cells and eliminates them via antibody-dependent cellular cytotoxicity (FcγR-mediated NK/macrophage killing), complement-dependent cytotoxicity (CDC), and induction of apoptosis.
Humanized IgG1 anti-GD2 monoclonal antibody that binds GD2 on neuroblastoma cells and mediates Fc receptor–dependent ADCC and complement-dependent cytotoxicity.
Humanized IgG1 anti-GD2 monoclonal antibody that binds GD2 on neuroblastoma cells and induces immune-mediated killing via Fcγ receptor–dependent antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Anti-GD2 IgG1 binds GD2 and recruits FcγR-expressing effector cells for ADCC and activates complement (CDC), lysing GD2-positive cells.